Search
Coagulation factor VII human
go.drugbank.com/drugs/DB13150ApprovedInvestigationalCoagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.
Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETClenbuterol
go.drugbank.com/drugs/DB01407ApprovedInvestigationalVet approvedA substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
Categories: Adrenergic beta-2 Receptor AgonistsTideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Synonyms: 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONENalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawnNalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist. … [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor.
Decamethonium
go.drugbank.com/drugs/DB01245ApprovedIt is a short acting depolarizing muscle relaxant. It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalWhile AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13). … Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus.
Myrrh
go.drugbank.com/drugs/DB11605ApprovedInvestigationalExtractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082] … Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching.
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalInfliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469].
Categories: Tumor Necrosis Factor Receptor Blocking ActivitySonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding … Sonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies.